is nivolumab chemotherapy or immunotherapy?
158949
Opdivo (nivolumab) is considered a type of immunotherapy drug, the first drug in this category approved for lung cancer (in 2015) and also now approved for several other cancers. Immunotherapy is a relatively new type of cancer treatment which uses the immune system or principles of the immune response to fight cancer.
1107316
Stomach cancer may be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy.
306774
['Ipilimumab (Yervoy)', 'Nivolumab (Opdivo)', 'Pembrolizumab (Keytruda)', 'Atezolizumab (Tecentriq)', 'Avelumab (Bavencio)', 'Durvalumab (Imfinzi)']
1136341
Nivolumab was previously approved to treat patients with advanced kidney cancer whose disease had gotten worse after treatment with standard first-line therapy. The new approval was based on results from an international phase 3 clinical trial.
640984
Non-Hodgkin lymphoma is usually treated with chemotherapy or radiotherapy, although some people may not need treatment straight away. In a few cases, if the initial cancer is very small and can be removed during a biopsy, no further treatment may be needed.
103234
It's the second immunotherapy drug approved for people with advanced SCLC, but the first approved for use as part of the initial (first-line) treatment. It's to be used along with chemotherapy for SCLC that has not already been treated with other drugs. About 10% to 15% of lung cancers are small cell lung cancer.
95775
Cyramza (ramucirumab) is a recombinant human IgG1 monoclonal antibody used a single-agent is for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
114919
One drug called ipilimumab (Yervoy®) blocks a checkpoint protein called CTLA-4. Two additional drugs, pembrolizumab (Keytruda®) and nivolumab (Opdivo®), target another checkpoint protein called PD-1. A third drug, atezolizumab (Tecentriq®), targets one called PD-L1.
16418
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with liver cancer (hepatocellular carcinoma) if you have previously received treatment with sorafenib.
1408299
Lymphocyte-depleting agents such as alemtuzumab and rituximab may cause prolonged immunosuppression. Providers should wait 6 months after administration of one of these drugs before administering any vaccine. Zoster vaccines are an exception and can be administered 1 month after discontinuing any immunomodulatory drug.
1142407
Kidney cancer is most often treated with surgery, targeted therapy, immunotherapy, or a combination of these treatments. Radiation therapy and chemotherapy are occasionally used. People with kidney cancer that has spread, called metastatic cancer (see below), often receive multiple lines of therapy.
1022212
How Does Nivolumab (Opdivo) Work? Nivolumab blocks the activity of a molecule called PD-1, a protein that prevents T cells from recognizing and attacking inflamed tissues and cancer cells. PD-1 can trick your immune system into overlooking melanoma cells as normal cells.
511612
Liver Cancer Treatment Options Immunotherapy treatments can enhance cancer-fighting immune system responses, but may not always be available or viable for patients with a history of hepatitis infection, as this type of immune system activity can damage normal, functioning liver cells.
1044726
Angioimmunoblastic T-Cell Lymphoma (AITL) is a rare, aggressive type accounting for about seven percent of all patients with T-cell lymphomas in the United States. Most patients are middle-aged to elderly and are diagnosed with advanced stage disease.
776994
['reslizumab (Cinqair)', 'mepolizumab (Nucala)', 'omalizumab (Xolair)', 'benralizumab (Fasenra)']
1441997
'Remarkable' Immunotherapy Trial Changes Advanced Lung Cancer Treatment. A large randomized trial finds Keytruda given with chemotherapy resulted in 20 percent improved survival at one year. Results from a new study will likely change the standard of care for advanced lung cancer.
986670
The Type 1 diabetes Immunotherapy Consortium. Immunotherapies are treatments that re-programme the immune system so that it no longer attacks and destroys insulin-producing beta cells in the pancreas. In the future, they could stop Type 1 diabetes in its tracks or prevent the condition entirely.